Chronic Pancreatitis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical and Experimental Pilot Study of Pregabalin in Patients With Chronic Pancreatitis
The aim of the study is to investigate the effect of pregabalin in pain resulting from chronic pancreatitis. The effect will be investigated by means of questionnaires concerning the daily experience of pain and the general quality of life. Furthermore the patients will be invited to participate in experimental testing with a multimodal pain model. The experimental testing will include stimulation of the skin, muscle and visceral tissue. The results from the experimental part of the study may help us to understand the mechanisms of action of pregabalin in this patient population.
Background and Rationale
The aetiology of pain in chronic pancreatitis remains to be elucidated. Therefore no common
guidelines for the management of the pain exist and it is a topic of great discussion. The
area is further complicated by the fact that only a few clinical trials have been carried
out (Wilder-Smith et al. 1999). The best attempt to establish clear guidelines for the
treatment of chronic pancreatitis is "American Gastroenterological Association Medical
Position Statement: Treatment of Pain in Chronic Pancreatitis" (Warshaw et al. 1998).
Initial treatment consists of low fat diet and non-narcotic analgesics, which can be
supplemented by oral pancreatic enzymes and proton pump inhibitors. If an acceptable level
of pain relief is not obtained with these drugs, only opioids remain for the management of
pain. Opioids have a number of well-known adverse effects including elevation of smooth
muscle tone (affecting gastrointestinal motility), toxicity in the central nervous system
and especially induction of addiction. Many patients suffering from chronic pancreatitis
have a history of alcoholic abuse making opioids, with their associated abuse potential,
less suitable for these patients. Alternatives to medical treatment exist in the form of
nerve blockade, lithotripsy and surgical treatment. However, results from studies of
non-medical treatment modalities are equivocal and medical analgesic therapy must still be
considered as the first choice in the management of painful chronic pancreatitis. Thus the
importance of identifying potential new treatment regimes for the treatment of pain in
chronic pancreatitis is clear.
In patients with chronic pancreatitis the pancreatic nerves have been found to have a
greater diameter and the area innervated by a single nerve is smaller (Bockman et al. 1988).
A neural genesis of pain therefore seems likely. The basis of the neurogenic generation of
pain may be due to an altered expression of neuropeptides like SP and CGRP. The
concentration of nerve growth factor (NGF) and its receptor TrkA is increased in
inflammatory areas which may lead to an enhanced transcription of SP and CGRP, both of which
are transmitters in the pain system (Di Sebatiano et al. 2003). Interestingly, the release
of SP is known to be reduced by agents such as pregabalin.
Support for a neuropathic component of the pain of chronic pancreatitis is also found in
clinical observations, where the pain is typically described as largely constant background
pain with shooting, burning and lancinating episodes that may mimic that seen in peripheral
neuropathies. Finally, evidence for central neuroplastic findings and strong descending
inhibition, which may reflect the pain mechanisms in neuropathic pain have been found in
recent studies (Dimcevski et al. 2006 and 2007). Thus inflammatory and "true" visceral pain
components appear to play a role in pancreatic pain. Hence the potential to extrapolate from
clinical trials demonstrating the activity of pregabalin in the treatment of neuropathic
pain to the treatment of the possible neuropathic component of chronic pancreatitis is of
great interest.
Central sensitization is an essential factor in the development of neuropathic pain (Baron
2001, Johnson et al. 2001) and in animal experiments the NMDA receptor has been shown to be
involved in this process. Calcium plays a central role, as an increased influx of calcium
into the neuron is observed when the NMDA receptor is activated. The enhanced concentration
of intracellular calcium functions as a second messenger for a number of neurotransmitters
and calcium thus contributes to the maintenance of the central sensitization (Nicholson
2000).
Pregabalin exerts a range of effects in pain transmission and although the precise mechanism
of action is not completely understood, it likely involves the binding of the drug to
calcium channels in the central nervous system (Ben-Menachem 2004). In animal experiments it
has been shown that pregabalin primarily exerts its effect in the dorsal horn, where a
reduced pain signal is seen. Pregabalin is a ligand of the α2-δ subunit of the voltage-gated
calcium channel and binding of pregabalin to this site results in reduced calcium influx at
the nerve terminals and therefore a reduced release of several excitatory neurotransmitters,
including glutamate, substance P (SP), calcitonin-gene related peptide (CGRP) and
noradrenaline. This may result in inhibition or reduction of the sensitization mentioned
above. Moreover, this may be the basis for the analgesic effect. It has been shown, in
animal experiments, that binding of pregabalin to calcium channels is able to counteract
central sensitization in the dorsal horn.
The evidence for the clinical effect of pregabalin in neuropathic pain is substantial and is
documented in a number of randomized clinical trials (Dworkin et al. 2003, Sabatowski et al.
2004, Rosenstock et al. 2004). The recommended dose for treating neuropatic pain is between
150 mg to 600 mg daily, which is similar to the dose chosen for this study. By the opinion
of the principal investigator no clinically relevant medical interactions are described for
pregabalin when administered for chronic pancratitis patients.
Pregabalin is absorbed in the small intestine by a saturable transporter (Piyapolrungroj et
al. 2001). It is well known that pancreatitis patients suffer from malabsorption of fat and
therefore frequently suffer from diarrhea. This could lead to changes in the mucosal surface
in the small intestine, and possibly change the absorption of pregabalin. Drug absorption
has never been investigated in patients suffering from pancreatitis and the simple and
linear kinetics of pregabalin makes it possible to study how drug absorption may vary in
these patients. A poorer absorption of drugs could partly explain why pain from pancreatitis
is difficult to relieve.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03112759 -
Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis
|
N/A | |
Enrolling by invitation |
NCT05410795 -
Establishment and Verification of Pancreatic Volume Formula Based on Imaging
|
||
Active, not recruiting |
NCT02965898 -
The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis
|
N/A | |
Completed |
NCT01452217 -
Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02868047 -
Establishing Standards for Normal Pancreatic EUS
|
N/A | |
Completed |
NCT00685087 -
A Prospective Study of Natural History of Pancreatitis
|
N/A | |
Completed |
NCT04949828 -
Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
|
||
Recruiting |
NCT06068426 -
Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management
|
N/A | |
Active, not recruiting |
NCT05764629 -
An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
|
||
Active, not recruiting |
NCT05042284 -
Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis
|
N/A | |
Completed |
NCT03850977 -
Is There an Association Between Chronic Pancreatitis and Pulmonary Function
|
||
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Recruiting |
NCT06015945 -
Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis
|
N/A | |
Completed |
NCT04619511 -
Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
|
||
Completed |
NCT03283566 -
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT
|
Phase 2 | |
Recruiting |
NCT03434392 -
QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing
|
N/A | |
Completed |
NCT01318369 -
Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain
|
Phase 2 | |
Completed |
NCT01430234 -
Enzyme Suppletion in Exocrine Pancreatic Dysfunction
|
Phase 4 | |
Terminated |
NCT01442454 -
Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis
|
N/A | |
Completed |
NCT00414908 -
A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
|
Phase 3 |